메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform

More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark A potential game changer that addresses both the pain of injections and the low efficiency of oral formulations In the obesity treatment market, delivery technology is expected to be the decisive factor shaping future leaders SEOUL, South Korea, Aug. 13, 2025 -- Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that t
- 김갑성 기자
- 2025-08-13 15:36
Hospital Management Asia 2025: Shaping the Future of Asian Healthcare

HO CHI MINH CITY, Vietnam, Aug. 13, 2025 -- Hospital Management Asia (HMA), the region's premier annual event for hospital management and healthcare, is set to officially take place at GEM Center, Ho Chi Minh City. This year's conference, organised by Clarion Events Pte Ltd, will gather over 100 speakers from 15 countries and territories, alongside hundreds of hospital leaders, medical professionals, and healthcare organizations from across the region and beyond. From Healthcare System Reform to Medical Tourism Under the theme "Quality, Experience & Leadership i
- 김갑성 기자
- 2025-08-13 15:19
Prince Court Medical Centre Strengthens Malaysia's Position as a Global Healthcare Destination with First Kelly Procedure

KUALA LUMPUR, Malaysia, Aug. 13, 2025 -- Prince Court Medical Centre has placed Malaysia firmly on the global medical tourism map by successfully performing the country's first Kelly procedure, an advanced reconstructive surgery for rare congenital urological conditions. On 11 August, a two-year-old boy from Indonesia underwent the pioneering surgery, jointly led by Dr. Roger Anthony Idi, Consultant Urologist at Prince Court, and Professor Imran Mushtaq, a world-renowned paediatric urologist recognised internationally for his expertise in complex reconstructive surgery for rare
- 김갑성 기자
- 2025-08-13 15:16
정밀 의료, 한국에서 60조원의 경제 효과 및 치료 패러다임 전환 예고

[ 메디채널 김갑성 기자 ] 정밀 의료 접근성 향상 위해 규제 및 시스템적 개선 필요 서울, 대한민국, 2025년 8월 13일 -- 글로벌 전략 컨설팅 기업 'L.E.K. 컨설팅'이 오늘 발표한 백서 '정밀 의료 사례 연구 보고서(On the Cusp of a Cure)'에 따르면, 정밀 의료 시대가 본격화되면 향후 10년간 한국에서 약 60조 원의 경제 효과와 보건의료 전반에 걸친 사회•경제적 가치가 실현될 것으로 전망된다. 정밀 의료는 기존의 획일적인 치료 방식과 달리 환자 개개인의 유전적 정보와 질병 특성에 기반해 맞춤형 치료를 제공하는 새로운 접근 방식으로, 질환에 대해 근본적인 치료 가능성을 제시한다. 유전자 치료제, 표적 항체 치료제, 약물-기기 복합 치료제, 정밀 진단 기술이 정밀 의료의 대표적인 핵심 기술이다. 이번 보고서는 글로벌 컨설팅 회사 L.E.K. 컨설팅과 아시아태평양 지역 16인의 전문가 자문위원회가 함께 개발한 것으로, '전체 시스템 이익 모델링(whole system benefits modelling)'을 활용해 한국에서 정밀 의료가 가져올 경제 및 보건의료적 효과를 분석했다.
- 김갑성 기자
- 2025-08-13 10:51
KBP's Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration

SINGAPORE, Aug. 13, 2025 -- KBP Biosciences Pte. Ltd. (the "Company") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr. Huang"), in support of arbitration proceedings respectively commenced by the Company and by Novo Nordisk A/S ("Novo Nordisk"). Following the Court's judgment today, the validity of the injunction application sought by Novo Nordisk will be determined via the arbitral
- 김갑성 기자
- 2025-08-13 09:44
Second heartbeat

BEIJING, Aug. 13, 2025 -- A news report from chinadaily.com.cn In this documentary, three patients suffered from advanced heart failure share their stories of how China's independently-developed non-contact full maglev artificial heart brought hope to their lives. Click to learn more!
- 김갑성 기자
- 2025-08-13 09:34
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

[ 메디채널 김갑성 기자 ] - The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy. - ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in efficacy than ASC47 low dose in combination with semaglutide, 87% vs 55%, respectively, in the DIO mouse model. - The combination of ASC47 low dose with tirzepatide also restored the body composition of obese mice to the level of healthy non-obese mice. A
- 김갑성 기자
- 2025-08-13 07:00
글로벌 스탠다드 조직문화 건강도 진단, Health Score 출시

[ 메디채널 김갑성 기자 ] 서울, 대한민국, 2025년 8월 13일 -- 오늘 8월 13일(수), HPTW 코리아가 공식 출범하며 한국 시장에서의 첫 발걸음을 내디뎠다. 이번 출범을 계기로, 글로벌 진단 모델 'Health Score'가 국내에 본격 도입된다. Health Score는 직원과 조직의 건강을 정밀하게 측정하고, 이를 성과와 연결해 위기 상황에서도 지속가능한 고성과 문화를 만들어가는 데 힘을 보태는 혁신적인 평가•인증 프로그램이다. 특히 이번 출범과 함께 'Make Work Healthy 특별강연 및 Health Score 온라인 진단 인증설명회'가 열린다. Health Score를 만든 창시자이자 『Make Work Healthy』의 저자인 존 라이언(John Ryan)이 직접 발표하며, 참가자는 무료로 신청 가능하고, 『Make Work Healthy』 도서도 증정된다. HPTW는 아일랜드 Dublin University에 본사를 두고, 영국•스칸디나비아•멕시코•브라질•필리핀•아랍에미리트•루마니아 등 전 세계 20여 개국에서 운영되고 있다. 글로벌 파트너인 Roffey Park Institute와 협력해 다수의
- 김갑성 기자
- 2025-08-13 07:00
MindHYVE.ai Partners with ICS Pakistan and NEI Pakistan to Revolutionize Nursing Education with AI-Powered ArthurAI

ISLAMABAD, Aug. 13, 2025 --In a pioneering step towards elevating nursing education in Pakistan, MindHYVE.ai has signed strategic Memorandum of Understanding (MoU) with the Institute of Contemporary Studies (ICS) and the National Excellence Institute (NEI). Pakistan faces a critical shortage of nursing professionals, with approximately 0.47 nurses and midwives per 1,000 people—significantly below the World Health Organization's recommended minimum of 2.5 per 1,000 (World Bank, 2019; International Labour Organization). In clinical settings, the ideal nurse-to-patient rat
- 김갑성 기자
- 2025-08-13 06:00
VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology

WENZHOU, China, Aug. 13, 2025 -- Recently, VivaVision Biotech (Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board. Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, is currently a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine; he is also a professor of medicine (immunology and rheumatology) and professor of pediatrics at Stanford. Dr. Nguyen serves as principal investigator on multiple clinical trials sponsored by the National Eye Institute and other or
- 김갑성 기자
- 2025-08-13 00:00

이전

11 12 13 14 15 16 17 18 19 20

많이 본 기사

최근기사

2025-08-30_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 08월 31일 01시 20분